Quotient (NASDAQ:QTNT) Rating Increased to Buy at BidaskClub

Quotient (NASDAQ:QTNT) was upgraded by analysts at BidaskClub from a “hold” rating to a “buy” rating in a research note issued on Friday, BidAskClub reports.

QTNT has been the subject of several other reports. Zacks Investment Research cut shares of Haynes International from a “hold” rating to a “sell” rating in a research note on Wednesday, May 8th. ValuEngine raised shares of XCel Brands from a “sell” rating to a “hold” rating in a research note on Tuesday, July 9th.

NASDAQ:QTNT opened at $10.49 on Friday. Quotient has a 1-year low of $5.52 and a 1-year high of $11.15. The company has a debt-to-equity ratio of 72.27, a current ratio of 4.59 and a quick ratio of 3.98. The firm has a fifty day moving average price of $9.25.

Quotient (NASDAQ:QTNT) last released its earnings results on Tuesday, May 28th. The company reported ($0.41) earnings per share for the quarter, beating the consensus estimate of ($0.44) by $0.03. The firm had revenue of $8.28 million during the quarter, compared to the consensus estimate of $7.30 million. As a group, sell-side analysts anticipate that Quotient will post -1.59 EPS for the current year.

In other Quotient news, President Jeremy Stackawitz sold 21,495 shares of Quotient stock in a transaction on Wednesday, May 29th. The shares were sold at an average price of $9.93, for a total transaction of $213,445.35. Following the completion of the transaction, the president now directly owns 131,939 shares of the company’s stock, valued at $1,310,154.27. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Frederick Hallsworth acquired 3,150 shares of Quotient stock in a transaction on Thursday, June 13th. The shares were bought at an average cost of $8.70 per share, with a total value of $27,405.00. Following the completion of the transaction, the director now owns 74,398 shares of the company’s stock, valued at $647,262.60. The disclosure for this purchase can be found here. Insiders own 17.40% of the company’s stock.

A number of hedge funds have recently added to or reduced their stakes in QTNT. Niemann Capital Management Inc. bought a new position in Quotient during the first quarter worth $101,000. Resources Investment Advisors Inc. bought a new position in Quotient during the first quarter worth $105,000. Rehmann Capital Advisory Group bought a new position in Quotient during the first quarter worth $154,000. Westfield Capital Management Co. LP bought a new position in Quotient during the first quarter worth $217,000. Finally, Knott David M boosted its position in Quotient by 1.8% during the first quarter. Knott David M now owns 170,000 shares of the company’s stock worth $1,532,000 after purchasing an additional 3,000 shares during the period. 63.91% of the stock is owned by hedge funds and other institutional investors.

Quotient Company Profile

Quotient Limited, a commercial-stage diagnostics company, develops, manufactures, and commercializes conventional reagent products used for blood grouping in the transfusion diagnostics market worldwide. The company is developing MosaiQ, a proprietary technology platform, which provides tests for blood grouping and serological disease screening.

Further Reading: What is the Ex-Dividend Date in Investing?

Receive News & Ratings for Quotient Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quotient and related companies with MarketBeat.com's FREE daily email newsletter.